Skip to main content
Erschienen in: Clinical & Experimental Metastasis 8/2010

01.12.2010 | Research Paper

KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model

verfasst von: Lacey R. McNally, Danny R. Welch, Benjamin H. Beck, Lewis J. Stafford, Joshua W. Long, Jeffery C. Sellers, Zhi Q. Huang, William E. Grizzle, Cecil R. Stockard, Kevin T. Nash, Donald J. Buchsbaum

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

Identifying molecular targets for treatment of pancreatic cancer metastasis is critical due to the high frequency of dissemination prior to diagnosis of this lethal disease. Because the KISS1 metastasis suppressor is expressed at reduced levels in advanced pancreatic cancer, we hypothesized that re-expression of KISS1 would reduce metastases. Highly metastatic S2VP10 cells expressing luciferase (S2VP10L) were transfected with a FLAG-tagged version of KISS1 (KFM), KFMΔSS (with deleted secretion signal sequence), or pcDNA3 control plasmid (CP) and expression was confirmed by RTQ-PCR. SCID mice were implanted orthotopically with S2VP10L cells or transfectants and tumor growth and metastases were monitored using bioluminescence imaging. Mice with S2VP10L-KISS1 tumors developed fewer liver (98%) and lung (99%) metastases than S2VP10L. Unexpectedly, mice with S2VP10L-KFMΔSS tumors also had reduced liver and lung metastases, but had more metastases than mice with S2VP10L-KISS. KISS1 protein was found in the cytoplasm of both KFMΔSS and KISS1-expressing orthotopic tumors by immunohistochemistry. Metastases were not found in lungs of mice with S2VP10L-KISS1 tumors; whereas, KFMΔSS lung sections had regions of concentrated KISS1 staining, suggesting that secretion of KISS1 is needed to reduce metastasis significantly. These data suggest induction of KISS1 expression has potential as an adjuvant treatment for pancreatic cancer.
Literatur
1.
Zurück zum Zitat Hezel AF, Kimmelman AC, Stanger B, Bardeesy N, DePinho RA (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Develop 20:1218–1249CrossRefPubMed Hezel AF, Kimmelman AC, Stanger B, Bardeesy N, DePinho RA (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Develop 20:1218–1249CrossRefPubMed
2.
Zurück zum Zitat Wray CJ, Ahmad SA, Matthews JB, Lowy AM (2005) Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 128:1626–1641CrossRefPubMed Wray CJ, Ahmad SA, Matthews JB, Lowy AM (2005) Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 128:1626–1641CrossRefPubMed
3.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMed
4.
Zurück zum Zitat Breslin TM et al (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8:123–132CrossRefPubMed Breslin TM et al (2001) Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 8:123–132CrossRefPubMed
5.
Zurück zum Zitat Stathopoulos GP, Androulakis N, Souglakos J, Stathopoulos J, Georgoulias V (2008) Present treatment and future expectations in advanced pancreatic cancer. Anticancer Res 28:1303–1308PubMed Stathopoulos GP, Androulakis N, Souglakos J, Stathopoulos J, Georgoulias V (2008) Present treatment and future expectations in advanced pancreatic cancer. Anticancer Res 28:1303–1308PubMed
6.
Zurück zum Zitat Rinker-Schaeffer CW, O’Keefe JP, Welch DR, Theodorescu D (2006) Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 12:3882–3889CrossRefPubMed Rinker-Schaeffer CW, O’Keefe JP, Welch DR, Theodorescu D (2006) Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 12:3882–3889CrossRefPubMed
7.
Zurück zum Zitat Chirco R, Liu XW, Jung KK, Kim HR (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25:99–113CrossRefPubMed Chirco R, Liu XW, Jung KK, Kim HR (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25:99–113CrossRefPubMed
8.
Zurück zum Zitat Freije JM, MacDonald NJ, Steeg PS (1998) Nm23 and tumour metastasis: basic and translational advances. Biochem Soc Symposia 63:261–271 Freije JM, MacDonald NJ, Steeg PS (1998) Nm23 and tumour metastasis: basic and translational advances. Biochem Soc Symposia 63:261–271
9.
Zurück zum Zitat Stafford LJ, Vaidya KS, Welch DR (2008) Metastasis suppressors genes in cancer. Int J Biochem Cell Biol 40:874–891CrossRefPubMed Stafford LJ, Vaidya KS, Welch DR (2008) Metastasis suppressors genes in cancer. Int J Biochem Cell Biol 40:874–891CrossRefPubMed
10.
Zurück zum Zitat Steeg PS (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3:55–63CrossRefPubMed Steeg PS (2003) Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 3:55–63CrossRefPubMed
11.
Zurück zum Zitat Jiang Y, Berk M, Singh LS, Tan HY, Yin LH, Powell CT et al (2005) KISS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. Clin Exp Metastasis 22:369–376CrossRefPubMed Jiang Y, Berk M, Singh LS, Tan HY, Yin LH, Powell CT et al (2005) KISS1 suppresses metastasis in human ovarian cancer via inhibition of protein kinase C alpha. Clin Exp Metastasis 22:369–376CrossRefPubMed
12.
Zurück zum Zitat Stafford LJ, Xia CZ, Ma WB, Cai Y, Liu MY (2002) Identification and characterization of mouse metastasis-suppressor KISS1 and its G-protein-coupled receptor. Cancer Res 62:5399–5404PubMed Stafford LJ, Xia CZ, Ma WB, Cai Y, Liu MY (2002) Identification and characterization of mouse metastasis-suppressor KISS1 and its G-protein-coupled receptor. Cancer Res 62:5399–5404PubMed
13.
Zurück zum Zitat Masui T, Doi R, Mori T et al (2004) Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochem Biophys Res Commun 315:85–92CrossRefPubMed Masui T, Doi R, Mori T et al (2004) Metastin and its variant forms suppress migration of pancreatic cancer cells. Biochem Biophys Res Commun 315:85–92CrossRefPubMed
14.
Zurück zum Zitat Nagai K, Doi R, Katagiri F, Ito T, Kida A, Koizumi M, Masui T, Kawaguchi Y, Tomita K, Oishi S, Fujii N, Uemoto S (2009) Prognostic value of metastin expression in human pancreatic cancer. J Exp Clin Cancer Res 21:28–29 Nagai K, Doi R, Katagiri F, Ito T, Kida A, Koizumi M, Masui T, Kawaguchi Y, Tomita K, Oishi S, Fujii N, Uemoto S (2009) Prognostic value of metastin expression in human pancreatic cancer. J Exp Clin Cancer Res 21:28–29
15.
Zurück zum Zitat Katagiri F, Nagai K, Kida A, Tomita K, Oishi S, Takeyama M, Doi R, Fujii N (2009) Clinical significance of plasma metastin level in pancreatic cancer patients. Oncol Rep 21:815–819PubMed Katagiri F, Nagai K, Kida A, Tomita K, Oishi S, Takeyama M, Doi R, Fujii N (2009) Clinical significance of plasma metastin level in pancreatic cancer patients. Oncol Rep 21:815–819PubMed
16.
Zurück zum Zitat Akisawa N, Nishimori I, Iwamura T, Onishi S, Hollingsworth MA (1999) High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 258:395–400CrossRefPubMed Akisawa N, Nishimori I, Iwamura T, Onishi S, Hollingsworth MA (1999) High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 258:395–400CrossRefPubMed
17.
Zurück zum Zitat Kitamura N, Iwamura T, Taniguchi S, Yamanari H, Kawano K, Holli SR, Bramhall J, Schulz J, Nemunaitis PD, Brown BailletM, Buckels JA (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167CrossRef Kitamura N, Iwamura T, Taniguchi S, Yamanari H, Kawano K, Holli SR, Bramhall J, Schulz J, Nemunaitis PD, Brown BailletM, Buckels JA (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167CrossRef
18.
Zurück zum Zitat Hollingsworth MA, Setoguchi T (2001) High collagenolytic activity in spontaneously highly metastatic variants derived from a human pancreatic cancer cell line (SUIT-2) in nude mice. Clin Exp Met 18:561–571 Hollingsworth MA, Setoguchi T (2001) High collagenolytic activity in spontaneously highly metastatic variants derived from a human pancreatic cancer cell line (SUIT-2) in nude mice. Clin Exp Met 18:561–571
19.
Zurück zum Zitat Nash KT, Phadke PA, Navenot JM, Hurst DR, Accavitti-Loper MA, Sztul E, Vaidya KS, Frost AR, Kappes JC, Peiper SC, Welch DR (2007) Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 99:309–321CrossRefPubMed Nash KT, Phadke PA, Navenot JM, Hurst DR, Accavitti-Loper MA, Sztul E, Vaidya KS, Frost AR, Kappes JC, Peiper SC, Welch DR (2007) Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 99:309–321CrossRefPubMed
20.
Zurück zum Zitat Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB (2000) Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 278:175–184CrossRefPubMed Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB (2000) Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 278:175–184CrossRefPubMed
21.
Zurück zum Zitat DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, Vickers SM (2007) Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 13:5535s–5543sCrossRefPubMed DeRosier LC, Buchsbaum DJ, Oliver PG, Huang ZQ, Sellers JC, Grizzle WE, Wang W, Zhou T, Zinn KR, Long JW, Vickers SM (2007) Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 13:5535s–5543sCrossRefPubMed
22.
Zurück zum Zitat Longo R, Cacciamani F, Naso G, Gasparini G (2008) Pancreatic cancer: from molecular signature to target therapy. Crit Rev Oncol Hematol 68:197–211CrossRefPubMed Longo R, Cacciamani F, Naso G, Gasparini G (2008) Pancreatic cancer: from molecular signature to target therapy. Crit Rev Oncol Hematol 68:197–211CrossRefPubMed
23.
Zurück zum Zitat Dhar DK, Naora H, Kubota H, Maruyama R, Yoshimura H, Tonomoto Y et al (2004) Downregulation of KiSS-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma. Int J Cancer 111:868–872CrossRefPubMed Dhar DK, Naora H, Kubota H, Maruyama R, Yoshimura H, Tonomoto Y et al (2004) Downregulation of KiSS-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma. Int J Cancer 111:868–872CrossRefPubMed
24.
Zurück zum Zitat Kostadima L, Pentheroudakis G, Pavlidis N (2007) The missing kiss of life: transcriptional activity of the metastasis suppressor gene KISS1 in early breast cancer. Anticancer Res 27:2499–2504PubMed Kostadima L, Pentheroudakis G, Pavlidis N (2007) The missing kiss of life: transcriptional activity of the metastasis suppressor gene KISS1 in early breast cancer. Anticancer Res 27:2499–2504PubMed
25.
Zurück zum Zitat Prentice, LM, Klausen, C, Kalloger, S, Köbel M, McKinney S, Santos JL, et al (2007) Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med 5:33 Prentice, LM, Klausen, C, Kalloger, S, Köbel M, McKinney S, Santos JL, et al (2007) Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. BMC Med 5:33
26.
Zurück zum Zitat Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR (1996) KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 88:1731–1737CrossRefPubMed Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR (1996) KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 88:1731–1737CrossRefPubMed
27.
Zurück zum Zitat Lee JH, Welch DR (1997) Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 57:2384–2387PubMed Lee JH, Welch DR (1997) Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res 57:2384–2387PubMed
Metadaten
Titel
KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model
verfasst von
Lacey R. McNally
Danny R. Welch
Benjamin H. Beck
Lewis J. Stafford
Joshua W. Long
Jeffery C. Sellers
Zhi Q. Huang
William E. Grizzle
Cecil R. Stockard
Kevin T. Nash
Donald J. Buchsbaum
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 8/2010
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-010-9349-5

Weitere Artikel der Ausgabe 8/2010

Clinical & Experimental Metastasis 8/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.